



Name: Ahmad Omar Babalghith

Nationality: Saudi

Language spoken: Arabic and English

Contact information: (02)5270000 Ext 4656

E-mail: babalghith@yahoo.com

Specialty: Genetics

Qualifications:

1996- Jeddah, Saudi Arabia

BSC-King Abdulaziz University, Jeddah, Saudi Arabia

2001- University of Aberdeen, Scotland, UK

MSc in Medical Molecular Genetics, Department of Molecular and cell Biology

2007- University of Aberdeen, Scotland, UK

P.h.D in Medical Molecular Genetics (cancer genetics). Department of Medicine and therapeutic

Experience:

2008-present

Assistant Professor in the Department of Medical Genetics, UQU, SA

2002-2005 PhD student

The focus of my PhD degree was the identification of genetic events involved in bladder cancer progression and applying the identified genomic regions in investigation the roles of genes located in these regions in well-defined bladder cancer tissues using tissue microarray (TMA) and immunohistochemistry (IHC).

Sep1998-Dec1999

Working as Medical technologist in Diagnostic Microbiology Laboratory at King Abdul-Aziz University Hospital, Jeddah, Saudi Arabia.

June1997-July1998

Internship in: 9 months in Diagnostic Microbiology Laboratory, King Abdul-Aziz University Hospital, Jeddah, Saudi Arabia. This include various sections including (fresh media preparation, stool and urine culture, blood culture, sputum analysis, various wound swab culture, and antibiotic sensitivity tests), and in Diagnostic Immunology 3 months

June1996-May1997

Clinical rotations in diagnostic laboratories at King Abdul-Aziz University Hospital, Jeddah, Saudi Arabia. This include the following departments: Clinical chemistry, Cytology and histopathology, diagnostic microbiology (microbiology, parasitology and virology), diagnostic immunology, haematology, and blood bank.

FILED WORK EXPERIENCE

Genetic and cytogenetic

- I have experience in several aspects of cytogenetic procedures such as blood culture and preparation of human metaphase chromosome from blood of normal healthy individuals and from cancer cell lines, and human metaphase and anaphase chromosome slide spread.
- DNA extraction from normal healthy blood sample, cancer cell lines, and tissues.
- Labelling DNA using different labelling system includes nick translation.
- Extensive technology experience of Fluorescent *in situ* hybridisation (FISH) and comparative genomic hybridisation (CGH).
- Extensive technical and analysis experience of immunohistochemistry (IHC).
- Full experience in designing and creation of tissue microarray (TMA).
- Experience in polymerase chain reaction (PCR).
- Experience in western blot analysis.

- Experience in dealing with cell culture of human cancer cell lines.
- General experience with human chromosomes karyotyping.

Diagnostic microbiology

- Extensive experience in all routine diagnostic microbiology laboratory work in various area such as fresh media preparation, stool and urine culture and analysis, sputum culture and analysis, blood culture and analysis, swab culture from different part of the body and analysis, and antibiotic sensitivity tests.
- Experience in setting up programme for training in diagnostic microbiology laboratory
- Experience as clinical training instructor for undergraduate students from Faculty of Science and Faculty of medicine and allied science.

Clinical chemistry

- Extensive experience in the use and operate of various clinical chemistry autoanalysers.
- General experience in the use and operate various clinical chemistry instruments such as spectrophotometers and blood gas analysers.

Haematology and blood bank

- Extensive experience in the use and operate of various blood cell counter instruments, coagulation tests, coagulation factor assays, fibrometer, etc.
- Experience in performing all the routine blood bank investigations such cross match, blood grouping, separation of blood components and serological screening of donor blood.
- Performing all blood bank special tests.

- Setting up of the Hospital blood bank laboratory, staff laboratory training, stock control, and ensuring smooth and efficient running of the hospital blood bank.

Diagnostic immunology and virology

- Wide experience in performing of various clinical immunology tests such as serological tests for the detection of the presence of antibodies or antigens of parasitic, bacterial, and viral infections using several techniques such as Latex agglutination, Indirect haemagglutination, ELISA, RIA, and Immunofluorescence.
- Experience in performing hepatitis profile, HIV screening tests, and HIV confirmatory test using Western blot.

Other experience and responsibilities

- Course organiser at the department of Medical genetics at UQU, S.A
- Deeply involved in the administration and budget control of clinical laboratory at King Abdul-Aziz University Hospital, Jeddah, Saudi Arabia.
- Involved in health and safety in clinical laboratory at King Abdul-Aziz University Hospital, Jeddah, Saudi Arabia.

PUBLICATIONS

Published abstracts

McDonald S. L., Moir S. E., **Babalghith A. O.**, Stevenson D. A. J., Heys S. D., Wallace H. M., Schofield A. C. Characterisation of Docetaxel resistant breast cancer cell lines. *Br J Cancer* 2003; 88(suppl 1): 88.

Babalthith A, Stevenson DAJ, Brown PAJ, Haites NE, Schofield AC. Comparative genomic hybridization (CGH) identifies genetic events involved in bladder cancer progression. *Eur J Surg Oncol* 2003; 29: 802.

McDonald S. L., Moir S. E., **Babalthith A. O.**, Stevenson D. A. J., Heys S. D., Wallace H. M., Schofield A. C. Comparative genomic hybridisation analyses of genetic changes associated with docetaxel resistance in breast cancer cells. *Scot Med J* 2003; 48: 130.

Yong SM, Stewart KN, Pollock AM, **Babalthith A**, Pavlidou E, Alhasso A, Heys SD, Brown PAJ, Schofield AC, N'Dow JMO. Membrane bound mucins MUC1, MUC4 and MUC16/CA125 are preferentially expressed in muscle invasive bladder cancer. *J Urol* 2004; 171 (Suppl): 259

Yong SM, Stewart KN, **Babalthith A**, Grigor KN, Pavlidou E, Heys SD, N'Dow J, Schofield AC. Membrane-bound mucin expression in bladder cancer. *Eur J Surg Oncol* 2004; 30: 1027-1028

PRESENTATIONS

SPOKEN PRESENTATIONS

Yong SM, Stewart KN, Pollock AM, **Babalthith AO**, Pavlidou E, Heys SD, Brown PAJ, Schofield AC, N'Dow J. Tissue microarray technology to evaluate novel bladder cancer tumour markers: role of MUC1 in progressive bladder cancer. Royal College of Surgeons of Edinburgh Clinical and Scientific Meeting, Edinburgh, 5-7 November 2003.

Babalthith AO, Schofield AC, Stevenson DAJ, Brown PAJ, Haites NE. Comparative genomic hybridisation (CGH) identifies genetic events involved in bladder cancer progression. British Association of Surgical Oncology Meeting, London, 24-25 November 2003 (Alan Edwards Memorial Prize Award for best paper).

Yong SM, Stewart KN, Pollock AM, **Babalthith AO**, Pavlidou E, Alhasso A, Heys SD, Brown PAJ, Schofield AC, N'Dow J. Role of MUC4 in progressive and recurrent non-progressive bladder cancer. Urological Research Society Annual Meeting, London, 9 January 2004.

POSTER PRESENTATIONS

McDonald SL, Moir SE, **Babalthith A. O**, Stevenson DAJ, Heys SD, Wallace HM, Schofield AC. Characterisation of docetaxel resistant breast cancer cell lines. British Cancer Research Meeting, Bournemouth, 2-5 July 2003.

McDonald S. L., **Babalthith A. O.**, Moir S. E., David A.J. Stevenson, Heys S. D., Schofield A. C. Amplification of chromosome 7q21-q31 involved in resistance to docetaxel in human breast cancer cell lines. Scottish Society for Experimental Medicine. Aberdeen. 23rd May 2003 Received Sir James Black Award for best poster.

Babalthith A. O, Stevenson DAJ, Haites NE, Schofield AC. Comparative genomic hybridisation (CGH) identifies genetic events associated with bladder cancer progression. Joint Meeting of the Scottish Society for Experimental Medicine and the Scottish Cardiovascular Forum, Glasgow, 9 January 2004.

Yong SM, Stewart KN, Pollock AM, **Babalthith A**, Pavlidou E, Alhasso A, Heys SD, Brown PAJ, Schofield AC, N'Dow JMO. Membrane bound mucins MUC1, MUC4 and MUC16/CA125 are preferentially expressed in muscle invasive bladder cancer. American Urological Association Annual Meeting, San Francisco, 8-14 May 2004.

Yong SM, Stewart KN, **Babalthith A**, Grigor KN, Pavlidou E, Heys SD, N'Dow J, Schofield AC. Membrane-bound mucin expression in bladder cancer. British Association of Surgical Oncology, London, 22-23 November 2004.

Babalth A, Schofield AC, Pavlidou E, Yong SM, Mishriki SF, Cohen NP, Stewart KN, Brown PAJ. Identification of clinically important molecular factors involved in bladder cancer. NHS Grampian Research Symposium, Aberdeen, 14 December 2004.